section name header

Pronunciation

en-a-SID-a-nib

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification:

Indications

High Alert

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 57% absorbed following oral administration.

Distribution: Widely distributed to tissues.

Protein Binding: 98.5%.

Metabolism/Excretion: Metabolized by numerous CYP450 isoenzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) to an active metabolite (AGI-16903). Also metabolized by multiple UDP-glucuronosyltransferase (UGTs). AGI-16903 is also metabolized by multiple CYP450 isoenzymes and UGTs. 89% eliminated in feces (34% as unchanged drug); 11% eliminated in urine (<1% as unchanged drug).

Half-life: 7.9 days.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown4 hrunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

F and E: hypocalcemia, hypokalemia, hypophosphatemia.

GI: bilirubin, diarrhea, nausea, vomiting.

GU: fertility.

Hemat: differentiation syndrome, leukocytosis.

Metab: appetite.

Neuro: dysgeusia.
Misc: tumor lysis syndrome.

Interactions

Drug-Drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Idhifa